Pre-eclampsia as a 'three stage problem' - A workshop report

Placenta

Volumn 25, Issue 6, 2004, Pages 585-587

  Stepan, H ^a   Faber, R ^a   Froster, U G ^a   Heinritz, W ^a   Wallaschofski, H ^b   Dechend, R ^c   Walther, T ^d,e   Huppertz, B ^f  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c FRANZ VOLHARD CLINIC   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; AUTOANTIBODY; BETAMETHASONE; CORTICOSTEROID; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLPREDNISOLONE; PROLACTIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSCRIPTION FACTOR; VASCULOTROPIN RECEPTOR 1;

APOPTOSIS; CELL DIFFERENTIATION; CYTOTROPHOBLAST; DISEASE CLASSIFICATION; DOPPLER FLOWMETRY; DOSE RESPONSE; EARLY DIAGNOSIS; ENDOTHELIUM CELL; ENDOTHELIUM LESION; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC ANALYSIS; HELLP SYNDROME; HUMAN; HYPOXIA; INTRAUTERINE GROWTH RETARDATION; MATERNAL HYPERTENSION; MISSENSE MUTATION; NOMENCLATURE; NOTE; PATHOGENESIS; PLACENTA DEVELOPMENT; PLACENTA INSUFFICIENCY; PLACENTA PERFUSION; PREDICTION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; THROMBOPHILIA; TROPHOBLAST; VASCULAR SMOOTH MUSCLE; WORKSHOP;

EID: 2542628873     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.placenta.2003.11.012     Document Type: Conference Paper

References (10)

1. Stepan H, Heihoff-Klose A, Faber R. Pathological uterine perfusion in the second trimester is not associated with neutrophil activation. Hypertens Pregnancy 2003;22:239-45.
2. Faber R, Stepan H, Baumert M, Voss A, Walther T. Analysis of blood pressure waveform: a new method for the classification of hypertensive pregnancy disorders. J Hum Hvpertens 2004, in press.
3. Huppertz B, Black S, Kaufmann P. Trophoblast aponecrosis and maternal endothelial dysfunction. In: Critchley H, MacLean A, Poston L, Walker J, editors. Preeclampsia: RCOG Press; 2003a, p. 158-67.
4. Huppertz B, Kingdom J, Caniggia I, Desoye G, Black S, Korr H et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 2003b;24:181-90.
5. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, Wallukat G et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003;107:1632-9.
6. AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001;7:1003-9.
7. Santos RAS, Simoes e Silva AC, Maric C, Silva DMR, Machado RP, de Buhr I et al. Angiotensin-(1-7) is an endogeneous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100:8258-63.
8. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
9. Wallaschofski H, Donne M, Eigenthaler M, Hentschel B, Faber R, Stepan H, Koksch M, Lohman T. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001;86:5912-9.
10. Guillemot F, Nagy A, Auerbach A, Rossant J, Joyner AL. Essential role of Mash2 in extraembryonic development. Nature 1994;371:333-6.